SaxoCell Conference 2026

SaxoCell Conference 2026
Go back

SaxoCell Conference 2026

From Lab to Life: Advancing Cell and Gene Therapies Together

Join us at the SaxoCell Conference 2026 in Dresden, where leading minds from science,industry, and politics come together to shape the future of safe and accessible cell and genetherapies — bridging innovation and implementation.

The SaxoCell Conference 2026 is your opportunity to engage with experts, innovators, and decision makers in the field of cell and gene therapies. As part of the BMBF Clusters4Future initiative, SaxoCell is one of Germany’s leading centres dedicated to researching new applications and production methods for personalised therapies and ‘living drugs’.

What to Expect:

  • Insights into the latest scientific advancements in cell and gene therapies.
  • Opportunities to network with professionals from academia, industry, and policy.
  • Discussions on how Germany is contributing to the future of Cell and Gene Therapy.

Date: 02 – 03 June 2026
Location: Penck Hotel, Dresden

Whether you’re a scientist, industry leader, or policymaker, the SaxoCell Conference offers a platform to
exchange ideas and collaborate on shaping the future of healthcare.

You can find more information about SaxoCell at www.saxocell.de

Register now to be part of this important event!

https://eveeno.com/saxocell_conference_2026

BioRN members receive a 20 % discount.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
Study shows how lymph node architecture affects cancer growth

Study shows how lymph node architecture affects cancer growth

A new study maps the organisation of immune and stromal cells in lymph nodes and shows how loss of this organisation affects prognosis in certain lymphomas Summary Researchers from EMBL Heidelberg, Heinrich Heine University Düsseldorf (HHU), and Düsseldorf University Hospital (UKD) have succeeded for the first time in mapping the organisation of immune and stromal […]

read more
High-throughput testing of drugs on mini-tumors reveals vulnerabilities in meningiomas

High-throughput testing of drugs on mini-tumors reveals vulnerabilities in meningiomas

Meningiomas are the most common brain tumors. Until now, only two methods have generally been considered for treating them: surgery and radiation therapy. A research team in Heidelberg has now developed a potential new approach for effective systemic therapy. Its members from Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital (UKHD) tested the effectiveness […]

read more
Development of a method for improved monitoring of the early stages of bone marrow cancer

Development of a method for improved monitoring of the early stages of bone marrow cancer

An international team, including researchers from Heidelberg University’s Faculty of Medicine and Heidelberg University Hospital, has developed the PANGEA-SMM prognostic tool. This tool makes it possible to determine with greater accuracy than before whether a precancerous condition—known as “smoldering multiple myeloma”—is progressing and thus requires treatment. The free online tool for treatment teams is available […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp